Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 212

Results For "disease"

2476 News Found

Lecanemab granted Fast Track designation by the U.S. FDA
Biotech | December 24, 2021

Lecanemab granted Fast Track designation by the U.S. FDA

Alzheimer's disease is a serious, progressive and devastating disease with few treatment options


U.S. FDA issues Emergency Use Authorisation for Merck’s molnupiravir
News | December 24, 2021

U.S. FDA issues Emergency Use Authorisation for Merck’s molnupiravir

The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally


CanSinoBio’s Convidecia vaccine largely effective against Covid-19 in phase III trial
News | December 24, 2021

CanSinoBio’s Convidecia vaccine largely effective against Covid-19 in phase III trial

The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia


Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron
News | December 23, 2021

Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron

Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant


U.S. FDA approves Novartis Leqvio to lower cholestrol
Drug Approval | December 23, 2021

U.S. FDA approves Novartis Leqvio to lower cholestrol

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1


Merck acquires Chord Therapeutics to expand its neuroinflammatory pipeline
News | December 22, 2021

Merck acquires Chord Therapeutics to expand its neuroinflammatory pipeline

Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)


Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn
Biotech | December 22, 2021

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn

Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy


NMPA approves CStone's NDA for Cejemly
Drug Approval | December 21, 2021

NMPA approves CStone's NDA for Cejemly

The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients


WHO grants EUL for Covovax
Drug Approval | December 20, 2021

WHO grants EUL for Covovax

First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine


2022: Predictions for medical and healthcare industry
Opinion | December 20, 2021

2022: Predictions for medical and healthcare industry

2022 is going to be the year of opportunities and innovations from the medical industry in India